Clinical Trial Search

Phase 2 N=18 HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma

HPV-Related Squamous Cell Carcinoma · Head and Neck Squamous Cell Carcinoma

Primary: Progression-free Survival (PFS) at 2 Years — 75.5 percentage of patients

Dan Zandberg Results May 2026 44.4% serious AE View details

Phase 2 N=100 A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study

Head and Neck Cancer · Squamous Cell Carcinoma of the Head and Neck

Primary: Progression Free Survival (PFS) — 49.7; 35.3 percentage of participants — p=0.067

University of Chicago Results May 2026 20.0% serious AE View details

Phase 2 N=131 Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Neurotrophic Keratitis Subjects

Neurotrophic Keratitis

Primary: Efficacy as Assessed by Complete Corneal Healing — 21; 16 Participants

Claris Biotherapeutics, Inc. Results May 2026 10.3% serious AE View details

Phase 2 N=128 KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Carcinoma, Non-Small-Cell Lung

Primary: Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) — 5.4; 11.1; 4.4 Percentage of participants

Merck Sharp & Dohme LLC Results May 2026 35.4% serious AE View details

Phase 2 N=194 Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients

Pancreatic Cancer

Primary: Progression-free Survival (PFS) - Biomarker Enriched Population — 5.5; 7.3; 5.9 months

Trishula Therapeutics, Inc. Results May 2026 55.2% serious AE View details

Phase 2 N=260 A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed

Influenza, Human · Influenza in Birds · Respiratory Tract Infections

Primary: Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HI) Antibodies Against the H5N6 Strain — 5.48; 5.55; 5.47; 20.39 titer

Seqirus Results May 2026 3.9% serious AE View details

Phase 2 N=89 Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Lung Cancer · Lung Metastases

Primary: Clinically Significant Events (CSE) — 0.449 Proportion of subjects — p=<.0001

Vergent Bioscience, Inc. Results May 2026 13.5% serious AE View details

Phase 2 N=42 Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma · Grade 1 Follicular Lymphoma · Grade 2 Follicular Lymphoma

Primary: Complete Response (CR) — 38 Participants

University of Washington Results May 2026 11.9% serious AE View details

Phase 2 N=40 Krill Oil for Pain in Elders

Chronic Musculoskeletal Pain

Primary: Participants With 70% or Greater Adherence Based on Self-reported Daily Diary — 18; 17 Participants

University of Florida Results May 2026 0.0% serious AE View details

Phase 2 N=95 ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma

EGFRmutant Stage IIIB/C or IV Non-squamous NSCLC

Primary: Progression-Free Survival (PFS) Rate at 12-months — 9; 11 Participants — p=0.367

ETOP IBCSG Partners Foundation Results May 2026 44.7% serious AE View details

Phase 2 N=149 A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

NSCLC Stage IIIB · NSCLC Stage IV · EGFR Gene Mutation

Primary: Objective Response Rate (ORR) According to RECIST 1.1 — 39; 33 Participants

Centre Francois Baclesse Results May 2026 44.3% serious AE View details

Phase 2 N=16 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)

Pancreatic Cancer · Pancreatic Ductal Adenocarcinoma · Pancreatic Adenocarcinoma

Primary: Best Overall Response (BOR) — 0; 0; 3; 11 Participants

HonorHealth Research Institute Results May 2026 43.8% serious AE View details

Phase 2 N=29 Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer

Prostate Cancer · Multiple Myeloma · Smoldering Multiple Myeloma (SMM)

Primary: Response Rate of Curcumin & Piperine Supplementation in Patients on Active Surveillance for Either Early Stage Prostate Cancer or Patients on Observation for…

University of Rochester Results May 2026 3.5% serious AE View details

Phase 2 N=22 Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.

Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) · Pancreatic Ductal Adenocarcinoma

Primary: Study Drug-related Adverse Events — 3; 6; 3; 5 Participants

Sidney Kimmel Comprehensive Cancer Center at… Results May 2026 31.8% serious AE View details

Phase 2 N=58 GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

Primary: Surrogate Biomarker of Oxidative Stress by Mass Spectroscopy — -79.9; 13.3 micromole/M tyrosine

University of Alabama at Birmingham Results May 2026 17.2% serious AE View details